Progress of bispecific antibodies targeting immune checkpoints in treatment of tumors / 肿瘤研究与临床
Cancer Research and Clinic
; (6): 221-225, 2021.
Article
em Zh
| WPRIM
| ID: wpr-886037
Biblioteca responsável:
WPRO
ABSTRACT
Immune checkpoint is one of the most effective research targets for tumor immunotherapy. Immune checkpoint inhibitors, mainly programmed death receptor 1 and its ligand 1, have achieved good response rates in various tumor treatments, but some tumors still have low response rates. In recent years, bispecific antibodies have developed rapidly in the field of tumor research, because they can target multiple targets and play a combined role in tumor therapy, and can effectively inhibit tumor immune escape. This article reviews the research progress and clinical status of bispecific antibodies targeting immune checkpoints.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Cancer Research and Clinic
Ano de publicação:
2021
Tipo de documento:
Article